Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae
Status:
Completed
Trial end date:
2018-02-20
Target enrollment:
Participant gender:
Summary
The objectives of this study are to assess the safety, tolerability, clinical and
microbiological efficacy and pharmacodynamics of patients who have severe pneumonia caused by
Streptococcus pneumoniae after the intravenous administration of CAL02 in addition of
standard of care antibiotic treatment.